Marion Refici

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

Alex R. Shoemaker, Michael J. Mitten, Jessica Adickes et al. · Clinical Cancer Research · 2008 · 209 citations

Medicine, Oncology, Pharmacology +12

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Scott Ackler, Michael J. Mitten, Kelly Foster et al. · Cancer Chemotherapy and Pharmacology · 2010 · 121 citations

Medicine, Hematology, Oncology +12

ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>

Scott Ackler, Xiao Yu, Michael J. Mitten et al. · Molecular Cancer Therapeutics · 2008 · 73 citations

Medicine, Oncology, Pharmacology +13

Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models

Debra C. Ferguson, Luis E. Rodrı́guez, Joann P. Palma et al. · Clinical Cancer Research · 2005 · 22 citations · Full text

Medicine, Oncology, Pharmacology +16

Fcγ-receptor signaling augments the LPS-stimulated increase in serum tumor necrosis factor-α levels

Marion Refici, Dennis W. Metzger, Bernard P. Arulanandam et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 2001 · 10 citations

Life Sciences, Immunology, Pathology +17